Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).

Raquel Reisinger,Sergiusz Wesolowski,Umang Swami,Pedro C. Barata,Edgar J. Hernandez,Roberto Nussenzveig,Gordon Lemmon,Bennet Peterson,Chuck Hensel,Mehmet Asim Bilen,Elisabeth I. Heath,Lakshminarayanan Nandagopal,Philip J. Saylor,Hani M. Babiker,Manish Kohli,Sumanta K. Pal,Michael B. Lilly,Mark Yandell,A. Oliver Sartor,Neeraj Agarwal

Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).

2021

162Background: PARP inhibitors (PARPi) provide significant clinical benefit for men with aPC with BRCA 1 and BRCA 2 mutations. However, in clinical trials, pts with BRCA1 mutations appeared to deri...

Keywords:

Clinical trial
Prostate cancer
Cancer research
Cell-free fetal DNA
Poly ADP ribose polymerase
Medicine
Genomic Profile

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations